-
公开(公告)号：US20240092933A1
公开(公告)日：2024-03-21
申请号：US18511308
申请日：2023-11-16
Applicant: Immatics Biotechnologies GmbH
Inventor： Gabriele PSZOLLA , Martin HOFMANN , Meike HUTT , Sebastian BUNK , Felix UNVERDORBEN , Frank SCHWOEBEL , Dominik MAURER , Maike JAWORSKI , Claudia WAGNER , Florian SCHWOERER , Heiko SCHUSTER
CPC classification number: C07K16/30 , C07K16/2809 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/565 , C07K2317/73 , C07K2317/92
Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
-
公开(公告)号：US20220185888A1
公开(公告)日：2022-06-16
申请号：US17686358
申请日：2022-03-03
Applicant: Immatics Biotechnologies GmbH
Inventor： Martin HOFMANN , Felix UNVERDORBEN , Sebastian BUNK , Dominik MAURER
Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated viral peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.
-
公开(公告)号：US20210048442A1
公开(公告)日：2021-02-18
申请号：US16990701
申请日：2020-08-11
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Meike HUTT , Toni WEINSCHENK , Sebastian BUNK , Oliver SCHOOR , Linus BACKERT , Martin HOFMANN , Jens FRITSCHE , Felix UNVERDORBEN , Gisela SCHIMMACK , Florian SALOPIATA
IPC: G01N33/68
Abstract: The present invention relates to a method for the characterization of peptide:MHC binding polypeptides, e.g. by mass spectrometry and an analysis of the recognized peptide space, i.e. in order to identify peptides that can be bound in the context of their presentation by MHC, and those who cannot be bound.
-
公开(公告)号：US20190016801A1
公开(公告)日：2019-01-17
申请号：US16035403
申请日：2018-07-13
Applicant: Immatics Biotechnologies GmbH
Inventor： Martin HOFMANN , Felix UNVERDORBEN , Sebastian BUNK , Dominik MAURER
Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.
-
公开(公告)号：US20250034227A1
公开(公告)日：2025-01-30
申请号：US18785378
申请日：2024-07-26
Applicant: Immatics Biotechnologies GmbH
Inventor： Felix UNVERDORBEN , Sebastian BUNK , Martin HOFMANN , Meike HUTT , Timo MANZ , Nadine ASCHMONEIT , Maike JAWORSKI , Lena SCHMOHL , Claudia WAGNER , Dominik MAURER , Heiko SCHUSTER , Nora TREIBER
IPC: C07K14/725 , A61K38/00 , A61P35/00
Abstract: The present invention relates to antigen binding proteins that specifically bind to a tumor expressed melanoma-associated antigen (MAGE) B2 antigenic peptide in a complex with MHC. The antigen binding proteins are provided for use in the treatment of MAGEB2-expressing cancers. Further provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins.
-
Patent Agency Ranking
公开(公告)号：US20230348598A1
公开(公告)日：2023-11-02
申请号：US18331556
申请日：2023-06-08
Applicant: Immatics Biotechnologies GmbH
Inventor： Martin HOFMANN , Felix UNVERDORBEN , Sebastian BUNK , Dominik MAURER
CPC classification number: C07K16/2809 , C07K16/1045 , C07K16/2833 , C07K16/30 , C07K16/46 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/32 , C07K2317/626 , C07K2317/94
Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.
-
公开(公告)号：US20210032361A1
公开(公告)日：2021-02-04
申请号：US16943779
申请日：2020-07-30
Applicant: Immatics Biotechnologies GmbH
Inventor： Meike HUTT , Felix UNVERDORBEN , Sebastian BUNK , Dominik MAURER , Martin HOFMANN , Gabriele PSZOLLA , Sara YOUSEF , Claudia WAGNER , Frank SCHWOEBEL , Heiko SCHUSTER
IPC: C07K16/30 , C07K14/725 , A61P35/00
Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
-
公开(公告)号：US20240052054A1
公开(公告)日：2024-02-15
申请号：US18483174
申请日：2023-10-09
Applicant: Immatics Biotechnologies GmbH
Inventor： Meike HUTT , Felix UNVERDORBEN , Sebastian BUNK , Dominik MAURER , Martin HOFMANN , Gabriele PSZOLLA , Sara YOUSEF , Claudia WAGNER , Frank SCHWOEBEL , Heiko SCHUSTER
IPC: C07K16/30 , C07K14/725 , A61P35/00
CPC classification number: C07K16/30 , C07K14/7051 , A61P35/00 , C07K2317/32 , C07K2317/24 , C07K2317/622 , C07K2317/567 , C07K2317/92 , C07K2317/55 , C07K2317/565
Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.
-
公开(公告)号：US20220195044A1
公开(公告)日：2022-06-23
申请号：US17693323
申请日：2022-03-12
Applicant: Immatics Biotechnologies GmbH
Inventor： Martin HOFMANN , Felix UNVERDORBEN , Sebastian BUNK , Dominik MAURER
Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.
-
公开(公告)号：US20190135914A1
公开(公告)日：2019-05-09
申请号：US16180980
申请日：2018-11-05
Applicant: IMMATICS BIOTECHNOLOGIES GMBH
Inventor： Felix UNVERDORBEN , Sebastian BUNK , Martin HOFMANN , Dominik MAURER , Meike HUTT , Claudia WAGNER , Leonie ALTEN
IPC: C07K16/28 , C12N15/62 , C12N5/0783 , A61P35/00 , C07K14/775
Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.017 seconds)
